Beam Therapeutics

Update in progress

BEAM (NasdaqGS)

Company RatingNeutral
SectorHealthcare
IndustryBiotechnology

Beam Therapeutics is a Cambridge, Massachusetts biotech company focused on precision genetic medicines for serious diseases. Its programs include an autologous hematopoietic stem cell therapy for sickle cell disease, BEAM-302 and BEAM-304 liver-targeting lipid nanoparticles for alpha-1 antitrypsin deficiency and phenylketonuria, and BEAM-301 for glycogen storage disease type 1a. It develops the ESCAPE platform with antibody conditioning and edited HSCs, and BEAM-103, an anti-CD117 antibody. Partnerships include Pfizer, Verve Therapeutics, and Orbital Therapeutics.

Company score

Sentiment: 0.39; SentimentMeasures the overall tone of recent coverage and discussion about the company.−10 negative · 0 neutral · +10 positive
Environment: 0.00; EnvironmentAssesses the company’s environmental impact, risks, and sustainability practices.−10 negative · 0 neutral · +10 positive
Social: 0.38; SocialAssesses the company’s influence on employees, customers, communities, and wider society.−10 negative · 0 neutral · +10 positive
Governance: 0.05; GovernanceAssesses leadership, accountability, transparency, and business ethics.−10 negative · 0 neutral · +10 positive
Sustainability: 0.12; SustainabilityCombines environmental, social, and governance signals into an overall sustainability score.−10 negative · 0 neutral · +10 positive
Impact Score: 0.26; Impact ScoreCombines sentiment and sustainability performance into an assessment of the company’s overall impact.−10 negative · 0 neutral · +10 positive